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Abstract
IMPORTANCE Scarce data are available on the association of mineralocorticoid receptor antagonist
(MRA) use with outcomes in acute decompensated heart failure (ADHF).
OBJECTIVE To investigate the association of MRA use with all-cause mortality and hospital
readmission in patients with ADHF.
DESIGN, SETTING, AND PARTICIPANTS This cohort study examines participants enrolled in the
Kyoto Congestive Heart Failure (KCHF) registry, a physician-initiated, prospective, multicenter cohort
study of consecutive patients admitted for ADHF, betweenOctober 1, 2014, andMarch 31, 2016, into
1 of 19 secondary and tertiary hospitals throughout Japan. To balance the baseline characteristics
associated with the selection of MRA use, a propensity score–matched cohort design was used,
yielding 2068 patients. Data analysis was conducted from April to August 2018.
EXPOSURES Prescription of MRA at discharge from the index hospitalization.
MAIN OUTCOMES ANDMEASURES Composite of all-cause death or heart failure hospitalization
after discharge.
RESULTS Among 3717 patients hospitalized for ADHF, 1678 patients (45.1%) had received MRA at
discharge and 2039 (54.9%) did not. After propensity scorematching, 2068 patients (with amedian
[interquartile range] age of 80 [72-86] years, and of whom 937 [45.3%] were women) were
included. In thematched cohort (n = 1034 in each group), the cumulative 1-year incidence of the
primary outcome was statistically significantly lower in the MRA use group than in the no MRA use
group (28.4% vs 33.9%; hazard ratio [HR], 0.81; 95% CI, 0.70-0.93; P = .003). Of the components of
the primary outcome, the cumulative 1-year incidence of heart failure hospitalization was
significantly lower in theMRA use group than in the noMRA use group (18.7% vs 24.8%; HR, 0.70;
95% CI, 0.60-0.86; P < .001), whereas no difference in mortality was found between the 2 groups
(15.6% vs 15.8%; HR, 0.98; 95% CI, 0.82-1.18; P = .85). No difference in all-cause hospitalization was
observed between the 2 groups (35.3% vs 38.2%; HR, 0.88; 95%CI, 0.77-1.01; P = .07). In additional
analyses that stratified by left ventricular ejection fraction, the association of MRA use with the




Question Is use of mineralocorticoid
receptor antagonist at discharge
associated with better outcomes in
patients hospitalized for acute
decompensated heart failure?
Findings In this cohort study of 2068
propensity score–matched Japanese
patients hospitalized for acute
decompensated heart failure,
mineralocorticoid receptor antagonist
administered at discharge was
statistically significantly associated with
a lower risk for the primary composite
outcome of mortality or heart failure
readmission, although no difference in
all-cause death was observed.
Meaning Use of mineralocorticoid
receptor antagonist at discharge from
acute decompensated heart failure
hospitalizationmay be associated with
heart failure hospitalization but not with
lower mortality.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE Use of MRA at discharge from ADHF hospitalization did not
appear to be associated with lower mortality but was associated with a lower risk of heart failure
readmission. This finding suggests that MRA treatment at dischargemay haveminimal, if any, clinical
advantages.
JAMA Network Open. 2019;2(6):e195892. doi:10.1001/jamanetworkopen.2019.5892
Introduction
Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, have been
associated with reductions in mortality in patients with stable chronic heart failure with reduced
ejection fraction (HFrEF).1,2 In patients with stable heart failure with preserved ejection fraction
(HFpEF), a randomized clinical trial (RCT) has suggested that MRA is associated with reductions in
heart failure hospitalization, although the study did not meet the primary composite end point of
death from cardiovascular causes, aborted cardiac arrest, or heart failure hospitalization.3,4
In contrast, scarce data are available on the long-term outcomes of MRA use after discharge of
patients hospitalized for acute decompensated heart failure (ADHF).5 Because these patients had
experienced the acute exaggeration of heart failure and hospital admission, they had a high risk for
cardiac mortality and rehospitalization owing to worsening of heart failure.6 In addition, the
contemporary patient population hospitalized for ADHFmight be substantially different from stable
patients with heart failure who are enrolled in RCTs. The role of MRA in postdischargemanagement
needs to be investigated in patients with ADHF andmultiple comorbidities. Therefore, we sought to
explore the association betweenMRA administered at discharge from ADHF hospitalization and
clinical outcomes using the registry of a large contemporary all-comer study (Kyoto Congestive Heart
Failure [KCHF]) in Japan of patients with ADHF hospitalization.
Methods
StudyDesign, Setting, and Population
The KCHF is a physician-initiated, prospective, multicenter cohort study that enrolled consecutive
patients who were hospitalized for ADHF for the first time between October 1, 2014, and March 31,
2016. These patients were admitted into 19 secondary and tertiary hospitals, including rural and
urban as well as large and small institutions, throughout Japan. The study protocol was approved by
the institutional review board of each participating hospital. A waiver of written informed consent
from each patient was granted by the institutional review boards of Kyoto University and each
participating center because the studymet the conditions of the Japanese ethical guidelines for
epidemiological study and the US policy for protecting human research participants.7,8 This study
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline.
The details of the KCHF study design and patient enrollment are described elsewhere.9,10
Briefly, we enrolled all patients with ADHF, as defined by themodified Framingham criteria, who
were admitted to the participating hospitals and patients who underwent heart failure–specific
treatment involving intravenous drugs within 24 hours after hospital presentation. Patient records
were anonymized before analysis. Data analysis was conducted from April 2018 to August 2018.
Among the 4056 enrolled patients in the KCHF registry, 3785 patients (93.3%)were discharged
alive after hospitalization for ADHF. Clinical follow-up data were collected in October 2017. The
attending physicians or research assistants at each participating facility collected clinical events data
after the index hospitalization fromhospital medical records or frompatients, their relatives, or their
referring physicians (with patient consent).
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In the present study, we compared the clinical outcomes between patients who receivedMRA
at discharge and those who did not receive it. We excluded 11 patients for missing data on left
ventricular ejection fraction (LVEF) during the index hospitalization to stratify the analysis according
to LVEF. After further exclusions of 57 patients without any follow-up data after discharge, the study
population consisted of 3717 patients with known LVEF and postdischarge clinical follow-up data
(Figure 1).
Definitions
We defined the use of MRA (MRA use group) as any new or continued prescription of spironolactone
or eplerenone at discharge from the index hospitalization. The detailed definitions of baseline clinical
characteristics have been described previously.10
The primary outcomemeasure was a composite of all-cause death or heart failure
hospitalization after discharge from the index hospitalization. Other outcomemeasures included
heart failure hospitalization, all-cause death, cardiovascular death, sudden death, and any-cause
hospitalization. Death was regarded as cardiovascular in origin unless obvious noncardiovascular
causes could be identified. Cardiovascular death included death related to heart failure, sudden
death, death related to stroke, and death from other cardiovascular causes. Sudden death was the
unexplained death in a previously stable patient. Stroke was either ischemic or hemorrhagic that
required either acute or prolonged hospitalization and had symptoms that lastedmore than 24
hours. Heart failure hospitalization was due to worsening of heart failure, requiring intravenous drug
therapy.9 Heart failure was classified according to baseline LVEF as with reduced LVEF (<40%) or
with preserved LVEF (40%).
Laboratory tests were performed on patient admission. Missing laboratory values are presented
in eTable 1 in the Supplement.
Statistical Analysis
Categorical variables were presented as numbers with percentages and were compared with the χ2
test. Continuous variables were expressed as means with SDs or medians with interquartile range
andwere comparedwith an unpaired, 2-tailed t test when normally distributed or withWilcoxon rank
sum test when not normally distributed. Cumulative incidences were estimated by the Kaplan-
Meier method and compared using the log-rank test. To account for the competing risk of all-cause
Figure 1. Study Flowchart
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death, we also calculated cumulative incidence functions of heart failure hospitalization and
compared the differences between the 2 groups by Gray test in thematched cohort.11,12
We regarded the date of discharge as time 0 for clinical follow-up. We compared baseline
characteristics with clinical outcomes on the basis of the presence or absence of the use of MRA at
discharge from the index hospitalization. To balance the baseline characteristics associated with the
selection of MRA use, we used a propensity score–matched cohort design as themain analysis. We
also performed analysis in the entire cohort as the sensitivity analysis to explore the robustness of
the findings. We compared groups by intention-to-treat analysis, regardless of the discontinuation of
MRA during follow-up.
A logistic regressionmodel was developed tomake the propensity score for the choice of MRA
with 16 baseline variables that were clinically relevant to the choice of MRA treatment (Table 1).
Based on the estimated propensity score, patients in the group who did not receive MRA treatment
(no MRA use) were matched with those in the group who received MRA treatment (MRA use) by
using a 1:1 greedymatching technique.13 We compared the baseline characteristics and evaluated the
cumulative incidences using the propensity score–matched cohort. We estimated the hazard ratios
(HRs) and 95% CIs with Cox proportional hazards regression model. We conducted subgroup
analyses stratified by LVEF (<40% or40%) and other clinically relevant factors in the Coxmodels.
We assessed the interactions between the subgroup factors and the associations of MRA use in the
Cox models. For the sensitivity analysis using the entire cohort, MRA and the 25 clinically relevant
risk-adjusting variables were simultaneously included in the Cox models (Table 1). The continuous
variables were dichotomized by clinically meaningful reference values or median values. We
expressed the association of theMRA use group with the noMRA use group with all of the outcome
measures as HRs with 95% CIs.
To focus the association of LVEF, we performed post hoc analyses. First, we stratified the entire
cohort into the 2 strata by LVEF (<40%or40%) and calculated the propensity score for the choice
of MRA use in each LVEF stratum. Then, we generated the propensity score–matched cohort in the
same fashion as the main analysis and compared the differences between the 2 groups in each
LVEF stratum.
All statistical analyses were conducted by 2 of our physicians (H.Y. and Y.Y.) and our statistician
(T. Morimoto) using JMP, version 13.0, and SAS, version 9.4 (SAS Institute Inc) or R (R Project for
Statistical Computing). Two-tailed P < .05 was considered statistically significant.
Results
Patient Characteristics
In the study population of 3717 patients, 1678 (45.1%) patients had receivedMRA treatment at
discharge and 2039 (54.9%) did not. TheMRA treatment included spironolactone (median dose, 25
mg) in 1570 patients (93.6%) and eplerenone (median dose, 50mg) in 108 patients (6.4%).
Regarding the baseline clinical characteristics before matching, the patients in theMRA use group
were younger and had a lower prevalence of previous heart failure hospitalization, hypertension,
diabetes, dyslipidemia, previous percutaneous coronary intervention or coronary artery bypass
graft, renal dysfunction, and anemia (Table 1). No significant differences in bodymass index, atrial
fibrillation (AF) or atrial flutter (AFL), previous myocardial infarction, previous stroke, chronic lung
disease, malignant neoplasm, and dementia were observed between the 2 groups (Table 1). TheMRA
use group wasmore likely to have a hypertensive origin and AF or AFL at presentation, higher heart
rate, lower blood pressure, lower levels of blood urea nitrogen and potassium, and a reduced LVEF
(Table 1). Regarding medical treatment at discharge, angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker, β-blocker, and loop diuretics were more often prescribed in theMRA
use group (Table 1).
The propensity score matching yielded a total of 2068 patients: 1034 patients in theMRA use
groupwerematched to 1034 reference patients in the noMRA use group (main cohort: median [IQR]
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Table 1. Patient Characteristics of the Study Population in theMatched and Entire Cohort
Variable
No. (%)
Propensity Score-Matched Cohort Entire Cohort
MRA Use (n = 1034) No MRA Use (n = 1034) P Value MRA Use (n = 1678) No MRA Use (n = 2039) P Value
Clinical Characteristic
Age, median (IQR), y 80 (72-86) 80 (73-87) .37 79 (70-85) 81 (73-87) <.001
Age ≥80 ya,b 536 (52) 534 (52) .93 793 (47) 1135 (56) <.001
Female sexa,b 469 (45) 468 (45) .96 763 (45) 905 (44) .51
BMI, mean (SD) 23.0 (4.7) 22.8 (4.3) .26 23.0 (4.8) 22.8 (4.2) .20
BMI ≤22b 449 (46) 458 (46) .92 744 (47) 893 (46) .57
Origin
Ischemic heart disease 335 (32) 323 (31) .57 530 (32) 675 (33) .31
ACSb 61 (5.9) 58 (5.6) .78 86 (5.1) 119 (5.8) .34
Hypertensive heart disease 260 (25) 269 (26) .65 368 (22) 559 (27) <.001
Cardiomyopathy 159 (15) 144 (14) .35 318 (19) 238 (12) <.001
Valvular heart disease 200 (19) 210 (20) .58 338 (20) 397 (19) .61
Other heart disease 80 (7.7) 88 (8.5) .52 124 (7.4) 170 (8.3) .29
Medical history
Previous HF hospitalizationa,b 314 (30) 299 (29) .47 549 (33) 768 (39) <.001
Atrial fibrillation or flutterb 418 (40) 447 (43) .20 714 (43) 836 (41) .34
Hypertensiona,b 758 (73) 761 (74) .88 1135 (68) 1555 (76) <.001
Diabetesa,b 378 (37) 348 (34) .17 595 (35) 797 (39) .02
Dyslipidemia 380 (37) 413 (40) .14 612 (36) 840 (41) .003
Previous myocardial infarctiona,b 225 (22) 223 (22) .92 366 (22) 470 (23) .37
Previous strokeb 161 (16) 139 (13) .17 248 (15) 342 (17) .10
Previous PCI or CABG 248 (24) 250 (24) .92 392 (23) 561 (28) .004
Current smokingb 131 (13) 129 (13) .89 222 (13) 230 (12) .08
VT or VF 44 (4.3) 41 (4.0) .74 86 (5.1) 68 (3.3) .007
Chronic kidney disease 397 (38) 418 (40) .35 604 (36) 1033 (51) <.001
Chronic lung diseaseb 122 (12) 138 (13) .29 203 (12) 285 (14) .09
Malignant neoplasm 153 (15) 143 (14) .56 234 (14) 301 (15) .47
Dementia 187 (18) 177 (17) .56 281 (17) 373 (18) .21
Social background
Poor medical adherence 183 (18) 162 (16) .22 293 (17) 335 (16) .40
With occupation 146 (14) 128 (12) .24 261 (16) 233 (11) <.001
Daily life activities
Ambulatoryb 833 (81) 818 (80) .57 1352 (81) 1589 (79) .04
Use of wheelchair, outdoor only 66 (6.4) 82 (8.0) .16 109 (6.6) 165 (8.2) .06
Use of wheelchair, outdoor and indoor 92 (8.9) 91 (8.9) .97 141 (8.5) 195 (9.7) .22
Bedridden 39 (3.8) 33 (3.2) .49 59 (3.6) 70 (3.4) .89
Vital Signs at Presentation
BP, mm Hg
Systolic, mean (SD) 149 (34) 149 (34) .91 145 (34) 151 (36) <.001
<90a,b 19 (1.8) 25 (2.4) .36 48 (2.9) 47 (2.3) .29
Diastolic, mean (SD) 87 (24) 85 (24) .25 85 (24) 85 (24) .53
Heart rate, mean (SD), bpm 98 (27) 97 (29) .93 97 (27) 95 (28) .005
<60 bpmb 51 (4.9) 72 (6.9) .051 87 (5.2) 163 (8.1) <.001
Rhythms at presentation
Sinus rhythm 582 (56) 583 (56) .96 897 (53) 1173 (58) .01
Atrial fibrillation or flutter 376 (36) 386 (37) .65 652 (39) 703 (34) .006
NYHA class III or IVa,b 904 (87) 913 (88) .54 1456 (87) 1766 (87) .64
(continued)
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age, 80 [72-86] years; 937 [45.3%] women; mean [SD] LVEF, 46.7% [16.0%]). In thematched
cohort, baseline characteristics were well balanced between the 2 groups, except for the slightly but
statistically significantly better renal function in the MRA use group than in the noMRA use group
(Table 1).
Clinical Outcomes in theMatched and Entire Cohort
Themedian (interquartile range [IQR]) length of follow-up was 470 days (357-649 days), with a 96%
follow-up rate at 1 year. In the propensity score–matched cohort, the cumulative 1-year incidence of
the primary outcome measure (a composite of all-cause death or heart failure hospitalization) in the
Table 1. Patient Characteristics of the Study Population in theMatched and Entire Cohort (continued)
Variable
No. (%)
Propensity Score-Matched Cohort Entire Cohort
MRA Use (n = 1034) No MRA Use (n = 1034) P Value MRA Use (n = 1678) No MRA Use (n = 2039) P Value
Tests at admission
LVEF, mean (SD), % 46 (16) 47 (16) .11 44 (16) 48 (16) <.001
HFrEF (EF <40%)a,b 368 (36) 370 (36) .93 722 (43) 661 (32) <.001
BNP, median (IQR), pg/mL 699 (381-1228) 699 (402-1218) .71 700 (381-1216) 721 (403-1287) .20
NT-proBNP, median (IQR), pg/mL 4640 (2189-9690) 5530 (2947-9692) .14 4810 (2427-10 773) 6405 (3008-14 109) .003
Serum creatinine, median (IQR), mg/dL 1.0 (0.7-1.3) 1.1 (0.8-1.4) <.001 1.0 (0.8-1.3) 1.3 (0.9-1.9) <.001
eGFR, mean (SD), mL/min/1.73m2 50 (35-67) 45 (33-59) <.001 51 (37-67) 38 (24-55) <.001
<30 mL/min/1.73m2a,b 189 (18) 186 (18) .86 253 (15) 725 (36) <.001
Blood urea nitrogen, median (IQR),
mg/dL
22 (16-30) 23 (18-32) .001 21 (16-29) 26 (19-39) <.001
Albumin, mean (SD), g/dL 3.5 (0.5) 3.5 (0.5) .74 3.5 (0.5) 3.5 (0.5) .04
<3.0 g/dLb 130 (13) 122 (12) .54 210 (13) 270 (14) .52
Sodium, mean (SD), mEq/L 139 (4.3) 139 (4.1) .34 139 (4.3) 139 (4.1) .16
<135 mEq/Lb 131 (13) 101 (9.8) .04 222 (13) 211 (10) .007
Potassium, mean (SD), mEq/L 4.1 (0.6) 4.2 (0.6) .003 4.1 (0.6) 4.3 (0.7) <.001
≥5.0 mEq/La 96 (9.3) 108 (10) .38 135 (8.1) 297 (15) <.001
Hemoglobin, mean (SD), g/dL 11.8 (2.3) 11.6 (2.3) .18 11.9 (2.4) 11.2 (2.3) <.001
Anemia, No. (%)a,b 665 (64) 670 (65) .82 995 (59) 1462 (72) <.001
MRA before the index admissiona,b 117 (11) 112 (11) .73 522 (31) 129 (6.3) <.001
Medications at discharge
ACEI/ARB and β-blocker 464 (45) 463 (45) .96 819 (49) 742 (36) <.001
ACEI or ARBa,b 625 (60) 627 (61) .93 1051 (63) 1086 (53) <.001
β-Blockera,b 702 (68) 703 (68) .96 1203 (72) 1266 (62) <.001
Loop diureticsa,b 911 (88) 908 (88) .84 1541 (92) 1474 (72) <.001
Thiazide 40 (3.9) 63 (6.1) .02 73 (4.4) 145 (7.1) <.001
Tolvaptan 97 (9.4) 92 (8.9) .70 176 (10) 214 (11) .99
Digoxin 59 (5.7) 58 (5.6) .92 127 (7.6) 84 (4.1) <.001
Warfarin sodium 236 (23) 242 (23) .75 420 (25) 504 (25) .83
DOAC 230 (22) 244 (24) .46 379 (23) 381 (19) .003
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary
syndrome; ARB, angiotensin-receptor blocker; BMI, bodymass index (calculated as
weight in kilograms divided by height in meters squared); BNP, brain-type natriuretic
peptide; BP, blood pressure; CABG, coronary artery bypass graft; DOAC, direct oral
anticoagulant; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart
failure; HFrEF, heart failurewith reduced ejection fraction; IQR, interquartile range; LVEF,
left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist;
NT-proBNP, N-terminal-proBNP; NYHA, New York Heart Association; PCI, percutaneous
coronary intervention; VF, ventricular fibrillation; VT, ventricular tachycardia.
SI conversion factors: To convert albumin to grams per liter, multiply by 10; blood urea
nitrogen level to millimoles per liter, multiply by 0.357; BNP to nanograms per liter,
multiply by 1.0; eGFR tomilliliters per second per meters squared, multiply by 0.0167;
hemoglobin level to grams per liter, multiply by 10.0; potassium level to millimoles per
liter, multiply by 1.0; serum creatinine to micromoles per liter, multiply by 88.4; and
sodium tomillimoles per liter, multiply by 1.0.
a Variables relevant to the choice of MRAwere selected for logistic regressionmodel for
developing a propensity score for the choice of MRA.
b Risk-adjusting variables were selected for Cox proportional hazardmodels in the
unmatched cohort.
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MRA use group was statistically significantly lower compared with the noMRA use group (28.4% vs
33.9%; HR, 0.81; 95% CI, 0.70-0.93; P = .003) (Figure 2A). The cumulative 1-year incidence of
all-cause death was not statistically significantly different between the 2 groups (15.6% vs 15.8%; HR,
0.98; 95% CI, 0.82-1.18; P = .85) (Figure 2B and Table 2), whereas the cumulative 1-year incidence
of heart failure hospitalization in the MRA use group was statistically significantly lower than that in
the noMRA use group (18.7% vs 24.8%; HR, 0.70; 95% CI, 0.60-0.86; P < .001) (Figure 2C and
Table 2). The result was consistent with the result derived from the cumulative incidence function
curves accounting for the competing risk of death by Gray test (eFigure 1 in the Supplement).
Figure 2. Cumulative Incidence Rates of the Primary OutcomeMeasure in the Propensity
Score–Matched Cohort
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Log-rank P = .003 (A), P = .85 (B), and P < .001 (C).
MRA indicates mineralocorticoid receptor antagonist.
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In the subgroup analysis (Figure 3), no statistically significant interaction was observed
between the HRs for the primary outcomemeasure associated with the use of MRA and the clinically
relevant subgroup factors such as LVEF, age, sex, previous heart failure hospitalization, diabetes,
myocardial infarction, AF or AFL, New York Heart Association class, estimated glomerular filtration
rate, and use of the antagonists of the renin-angiotensin system and β-blocker (eTable 2 and eTable 3
in the Supplement). Nevertheless, the association of MRA use with the primary outcomemeasure
was greater in patients with HFpEF (25.9% vs 33.4%; HR, 0.75; 95% CI, 0.62-0.89; P = .001) than in
those with HFrEF (33.1% vs 34.7%; HR, 0.93; 95% CI, 0.74-1.18; P = .56) (Figure 3; eFigure 2 in the
Supplement).
In the entire cohort, the cumulative 1-year incidence of the primary outcomemeasure in the
MRA use group was statistically significantly lower than that in the noMRA use group (30.6% vs
36.8%; P < .001) (eFigure 3 in the Supplement). After adjusting for baseline characteristics, the
favorable association of theMRA use group compared with the noMRA use group remained
statistically significant (adjusted HR, 0.81; 95% CI, 0.71-0.92; P = .001) (Table 2). The results in the
entire cohort for the secondary outcome measures, including all-cause death and heart failure
hospitalization, were consistent with those in the propensity score–matched cohort (Table 2;
eFigure 3 in the Supplement). No difference in any unexpected hospitalization was observed
between the 2 groups in the propensity score–matched cohort (35.3% vs 38.2%; HR, 0.88; 95% CI,
0.77-1.01; P = .07), although the cumulative 1-year incidence of any unexpected hospitalization in the
MRA use group was statistically significantly lower than that in the no MRA use group in the entire
cohort (36.6% vs 40.8%; adjusted HR, 0.84; 95% CI, 0.74-0.96; P = .007) (Table 2). The results in
the entire cohort for the subgroup analysis stratified by LVEF (eFigure 4 and eTable 4 in the
Supplement) were consistent with those in the propensity score–matched cohort.
Post Hoc Analyses
Of the population of 3717 patients, 1383 (37.2%) showed reduced LVEF, and 2334 (62.8%) showed
preserved LVEF (eFigure 5 in the Supplement). Propensity score matching resulted in a total of 385
patients with HFrEF and 690 patients with HFpEF for the MRA use group or no MRA use group
(eFigure 5, eTable 5, and eTable 6 in the Supplement). In thematched cohort of patients with HFrEF,
the cumulative 1-year incidence of the primary outcomemeasure was not statistically significantly
different between the 2 groups (34.7% vs 33.7%; HR, 0.87; 95% CI, 0.78-1.21; P = .78) (eFigure 6 in
the Supplement). In the matched cohort of patients with HFpEF, the cumulative 1-year incidence of
Table 2. Clinical Outcomes in theMatched and Entire Cohort
Outcome
Propensity Score–Matched Cohort Entire Cohort
No. (%)a
HR (95% CI) P Value
No. (%)a












287 (28.4) 344 (33.9) 0.81
(0.70-0.93)
.003 503 (30.6) 739 (36.8) 0.79
(0.71-0.88)
<.001 0.81 (0.71-0.92) .001
HF hospitalization 179 (18.7) 239 (24.8) 0.70
(0.60-0.86)
<.001 335 (21.5) 494 (26.2) 0.77
(0.68-0.88)
<.001 0.74 (0.63-0.87) <.001
All-cause death 157 (15.6) 159 (15.8) 0.98
(0.82-1.18)
.85 257 (15.7) 367 (18.4) 0.83
(0.72-0.95)
.007 0.93 (0.78-1.11) .42
Cardiovascular
death
96 (9.8) 93 (9.4) 1.07
(0.84-1.36)
.59 155 (9.8) 217 (11.3) 0.88
(0.74-1.05)
.16 1.03 (0.82-1.29) .80
Sudden death 23 (2.5) 18 (1.9) 1.59
(0.93-2.78)
.09 33 (2.2) 43 (2.3) 1.09
(0.73-1.61)
.68 1.51 (0.92-2.45) .10
Any hospitalization 344 (35.3) 375 (38.2) 0.88
(0.77-1.01)
.07 580 (36.6) 779 (40.8) 0.85
(0.77-0.94)
.002 0.84 (0.74-0.96) .007
Abbreviations: HF, heart failure; HR, hazard ratio; MRA, mineralocorticoid receptor
antagonist.
a Number of patients with at least 1 event reported as cumulative 1-year incidence,
counted through the entire follow-up period.
b Adjusted for the clinically relevant variables described in Table 1.
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the primary outcomemeasure in theMRA use group was statistically significantly lower than that in
the no MRA use group (26.8% vs 33.7%; HR, 0.78; 95% CI, 0.66-0.93; P = .005) (eFigure 6 in the
Supplement). The results were consistent with themain results (eFigure 2 in the Supplement) in the
propensity score–matched cohort, including patients with HFrEF or HFpEF.
Discussion
The main findings of the present study were as follows. First, the use of MRA at hospital discharge
was associated with a lower risk for the primary outcomemeasure (a composite of all-cause death or
Figure 3. Subgroup Analysis for the Primary OutcomeMeasure in the Propensity Score–Matched Cohort































































































































































ACEI indicates angiotensin-converting enzyme
inhibitor; ARB, angiotensin-receptor blocker; eGFR,
estimated glomerular filtration rate; HF, heart failure;
HR, hazard ratio; LVEF, left ventricular ejection
fraction; MRA, mineralocorticoid receptor antagonist;
and NYHA, New York Heart Association.
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heart failure hospitalization) in patients hospitalized for ADHF; however, MRA use did not seem to be
associated with lower mortality but was associated with heart failure hospitalization. Second, when
patients were stratified by LVEF at first, some advantages appeared to have potentially accrued to
patients with HFpEF.
The clinical utility of MRA in stable patients with heart failure and reduced LVEF was first
demonstrated in the Randomized Aldactone Evaluation Study (RALES) in 1991.1 Subsequently, a line
of evidence emerged that MRA treatment (spironolactone or eplerenone) was associated with
reducedmorbidity andmortality in patients with HFrEF.2,14 The Treatment of Preserved Cardiac
Function Heart FailureWith an Aldosterone Antagonist (TOPCAT) trial15 in patients with stable HFpEF
suggested the reduction of heart failure hospitalization with MRA treatment, although the study
failed to show the evidence for themortality advantage of MRA treatment during themedian
follow-up of 3.3 years. However, to our knowledge, no previous RCT investigated the association of
MRA use in patients hospitalized for ADHFwith the postdischarge outcomes. Acute decompensated
heart failure has the potential risk for decline and eventually in-hospital death. Even during the
recovery phase, a certain proportion of patients hospitalized for ADHF are hemodynamically
unstable, often with worsening renal function. Therefore, the optimal management of patients
hospitalized for ADHFwould be defined specifically in this patient population. In the case of
β-blocker treatment, the heart failure guidelines recommend its early induction in patients with
ADHF and reduced LVEF, although the recommendation was based on small studies showing the
association between withdrawal of β-blocker therapy at admission for ADHF and an increase in
mortality.16-19
In the present study, MRA treatment was not associated with a lower risk for all-cause death but
instead with heart failure hospitalization only in contemporary patients with ADHFwhowere
discharged alive. To our knowledge, the baseline patient characteristics were substantially different
from those in previous RCTs. A large proportion of patients with advanced age (median age of 80
years) and a substantial proportion of patients with comorbidities, such as chronic kidney disease
and AF or AFL, were represented in this study. Despite these demographic differences, the favorable
association of MRA with heart failure hospitalization but not with mortality in patients with HFpEF
was consistent with findings reported in previous RCTs.
Themechanisms by whichMRAmay become potentially advantageous to patients with HFpEF
from the point of heart failure readmission rate are uncertain. However, the neurohormonal
pathways were excessively activated in a large proportion of patients with ADHF through
sympathetic nerve systems, worsening renal function, and the aggressive use of loop diuretics.20-22
The use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker was less
common in HFpEF than in HFrEF. Therefore, the blockade of the renin-angiotensin system byMRA
might have promoted the favorable association with heart failure hospitalization in patients with
HFpEF. Another possible mechanismwas the diuretic nature of MRA. In this study, the combination
of MRA and loop diuretics was more frequently observed in patients with HFpEF. Long-term use of
loop diuretics is associated with diuretic resistance through tubule-glomerular feedbackmechanisms
enhanced by renin-angiotensin-aldosterone system activation.20-22 The blockade of aldosterone
statistically significantly enhances the blockade of sodium reabsorption in the distal tubules and
collecting duct. These speculatedmechanisms were consistent with the observed favorable
associations of MRA use with the heart failure readmission in patients with HFpEF.
However, no difference in all-cause mortality or any unexpected hospitalization was observed
regardless of MRA use. One reason for this finding might be that many patients, particularly those
with HFpEF, hadmany comorbidities owing to their advanced age. Thus, the outcomes of MRAmay
be counterbalanced by electrolyte imbalance, worsening renal function, and noncardiovascular
mortality or hospitalization in patients who receivedMRA. Another consideration is that patients
treated with MRA in the entire population were hypotensive, more likely to have reduced LVEF, and
less likely to have ADHF from hypertensive heart disease. Therefore, the adverse effects of MRA use
may have been avoided because the heart failure stage in theMRA use group wasmore progressive
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than the noMRA use group, although we performed the propensity score matching using 16
variables.
The lack of mortality advantage fromMRA use despite a reduction in heart failure
hospitalization was consistent with findings of an observational study in patients with ADHF and the
TOPCAT trial.3,5,15 The therapy to reduce heart failure hospital readmissions has an important role in
daily practice in a rapidly aging society because repeated heart failure hospitalizations are associated
with highmortality rates, diminished quality of life and functional status, inadequate recovery after
heart failure deterioration, and the escalation of the medical costs.23 In contrast, the rate of any
unexpected hospitalization did not differ between theMRA use group and noMRA use group in the
propensity score–matched cohort. Considering no differences in mortality or overall rate of
hospitalization, MRA usemay be associated with minimal, if any, clinical net advantages. Our
additional analyses suggested the potential value of MRA use for patients with HFpEF. Exploratory
studies to identify the patient groups that find MRA use advantageous are needed and should be
confirmed by RCTs in patients hospitalized for ADHF.
Limitations
This study has several limitations. First, the observational study design is subject to selection bias and
residual confounding. The KCHF registry had comprehensive data on patient demographics, medical
history, underlying heart disease, prehospital activities, socioeconomic status, signs, symptoms,
medications, laboratory tests, electrocardiogram, and echocardiography results, acute management
in the emergency department, status at discharge, and clinical events during the index
hospitalization. By adjusting for 25 variables, we accounted for most conceivable confounders.
Nevertheless, residual unmeasured confounding could affect the results. Second, we had no
prescription data after discharge from the index hospitalization; therefore, we could not deny the
possibility of substantial crossover in MRA use. Third, this observational study used propensity score
matching. Thus, we did not perform a confidence set or power analysis in advance. Further studies,
including those on quality of life and cost, may clarify the clinical net advantage of MRA use in this
cohort. Fourth, data on the reasons for MRA use or no MRA use by individual patients were not
available.
Conclusions
Use of MRA at discharge from ADHF hospitalization appeared to be associated with a lower risk of
heart failure hospitalization but not with lower all-cause mortality or overall rate of hospitalization.
These findings suggest that MRA use might be associated with minimal, if any, clinical advantage.
Further studies appear to be needed to identify the patient groups that may find value in MRA
treatment and for findings to be confirmed by RCTs in patients hospitalized for ADHF.
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